Report post
BMY stock is currently crashing to a 52-week low, offering massive upside potential. Despite a 27% crash, Bristol-Myers Squibb remains undervalued with a 4.7% dividend yield. Our financial analysis estimates a 20% IRR. Is BMY a buy now? Explore our detailed stock analysis to make informed decisions.

The World's Leading Crypto Trading Platform

Get my welcome gifts